Does fetal fibronectin testing prevent preterm birth?
In a systemic review and meta-analysis, the authors assessed 6 high quality randomized clinical trials to determine whether the use of fetal fibronectin (FFN) in the clinical setting actually reduces preterm labor. Berghella and Saccone (AJOG, 2016) compared 546 singleton gestations that were randomized to management based on FFN results (intervention group) or not (comparison group). When comparing the intervention to the control group, the researchers found:
No differences in
Labor incidence at <37 weeks, <34 weeks <32 weeks and <28 weeks gestation
Number of women who delivered within 7 days
Mean gestational age at delivery
Rate of maternal hospitalization
Use of tocolysis or antenatal steroids
Mean time in the triage unit
Neonatal outcomes, including RDS, admission to the NICU
Statistical difference was identified in
Cost of hospitalization charges with a mean additional cost of $153 in the intervention group (95% CI, 24.01 – 281.99)
FFN is an extracellular matrix glycoprotein produced during pregnancy by amniocytes and cytotrophoblasts. Studies have shown that increased levels of FFN in vaginal and cervical secretions are associated with spontaneous preterm birth (SPTB). Obtaining FFN is easy and safe, using a swab, and FFN has been used to help providers determine whether to keep patients with symptoms of SPTB under surveillance. While clinical validity has been determined – increased FFN levels are associated with SPTB – this meta-analysis sought to determine clinical utility and whether outcomes are altered in a positive way.
Based on the findings of this paper, it appears that there is no clinical benefit but there are increased costs to the use of FFN in the management of singleton pregnancies with symptoms suggestive of SPTB
An editorial by GA Macones, MD, advocates that based on the findings in this study, the use of FFN testing in treated preterm labor is not justified
Studies that included the use of ultrasound measurement of cervical lengths were not included
Strengths of study include rigorous adherence to principles of evidence-based medicine, thereby reducing sources of bias
Limitations relate to the number of study subjects, and therefore stratification based on more individualized or particular clinical scenarios could not be assessed
Please log in to access ObGFirst and the 2T US Atlas
Media - Internet
Computer System Requirements
OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Jointly provided by
NOT ENOUGH CME HOURS
It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan